Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment.

D Raspadori1, D Rondelli, S Birtolo

  • 1Department of Hematology, University of Siena, Italy.

Leukemia
|August 18, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on fertility preservation: new opportunities and challenges in the fight against infertility.

La Clinica terapeutica·2022
Same author

Management of severe right lung cystic pulmonary interstitial emphysema in an infant at 24 weeks gestation with bedside selective left main stem bronchial intubation: Case report and review of the literature.

Journal of neonatal-perinatal medicine·2020
Same author

Late-onset presentation and phenotypic heterogeneity of the rare R377W PSEN1 mutation.

European journal of neurology·2020
Same author

Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.

European review for medical and pharmacological sciences·2020
Same author

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.

Leukemia·2019
Same author

MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3. It is a cost-effective genetic test.

European review for medical and pharmacological sciences·2018
Same journal

Evolutionary considerations for risk stratification in TP53-variant myeloproliferative neoplasms.

Leukemia·2026
Same journal

Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

Leukemia·2026
Same journal

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.

Leukemia·2026
Same journal

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same journal

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same journal

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Leukemia·2026
See all related articles

Treatment for hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (2-CdA) significantly reduces naive CD4+/CD45RA+ T cells, suggesting this subset is sensitive to 2-CdA toxicity. Memory CD4+/CD45RO+ T cells increase proportionally post-treatment.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • CD45 isoforms (CD45RA and CD45RO) distinguish naive and memory CD4+ T cells.
  • Hairy cell leukemia (HCL) is associated with T cell abnormalities.
  • Previous studies noted reduced CD4+/CD45RO+ T cells in HCL patients.

Purpose of the Study:

  • To evaluate CD45RA and CD45RO expression on CD4+ T cells in HCL patients.
  • To compare T cell subsets in untreated HCL patients, treated HCL patients, and healthy controls.
  • To assess the impact of 2-chlorodeoxyadenosine (2-CdA) treatment on T cell populations.

Main Methods:

  • Three-color flow cytometry was used to analyze CD45RA and CD45RO expression on CD4+ T cells.
  • The study included 38 HCL patients (19 untreated, 19 treated with 2-CdA) and healthy controls.

Related Experiment Videos

  • Treated patients received 0.1 mg/kg/day of 2-CdA for 7 days.

    • Main Results:

    • Untreated HCL patients showed similar CD4+ T cell subsets to controls.
    • 2-CdA treated HCL patients (3-5 years post-treatment) exhibited significantly reduced CD4+/CD45RA+ cells compared to untreated patients and controls.
    • Treated patients showed a higher proportion of CD4+/CD45RO+ cells relative to untreated patients and controls.

    Conclusions:

    • CD4+/CD45RA+ (naive) T cells are significantly depleted after 2-CdA treatment in HCL patients.
    • CD4+/CD45RO+ (memory) T cells increase proportionally following 2-CdA therapy.
    • These findings suggest that naive CD4+ T cells are more susceptible to the toxic effects of 2-CdA.